Department of Internal Medicine, Batangas Medical Center, Batangas City, Philippines.
Department of Internal Medicine, Batangas Medical Center, Batangas City, Philippines.
Clin Nutr ESPEN. 2023 Feb;53:134-143. doi: 10.1016/j.clnesp.2022.12.005. Epub 2022 Dec 6.
Malnutrition, as defined by the World Health Organization (WHO), includes undernutrition. In the Philippines, malnutrition is common due to several factors. The nutritional biomarkers can be used as an alternative indicator of dietary intake and nutritional status that can detect deficiencies in support to clinical management of COVID-19 patients. Apart from that, biomarkers are potentially useful for screening, clinical management, and prevention of serious complications of COVID-19 patients. Serum albumin, c-reactive protein (CRP), leukocyte count, lymphocyte count, blood urea nitrogen (BUN) to compute the nutritional prognostic indices (Prognostic nutritional index (PNI) score, BUN/Albumin ratio (BAR) and CRP/Albumin ratio (CAR).
To compare the nutritional biomarkers of patients with COVID-19 based on case severity and determine the nutritional prognostic indices and associate to patients' clinical outcome during hospital stay.
A single center, cross-sectional study was performed between June 2021 to August 2021 in a COVID-19 designated referral center in CALABARZON which comprised of 167 patients as part of the study. Clinicodemographic profile including patients' age, sex, co-morbidities, weight, height, laboratory, and serum biomarkers during the first 48 h of admission (serum albumin, leukocyte count, lymphocytes count, CRP, and BUN) were collated wherein the nutritional prognostic indices were computed and analyzed. Clinical outcomes of the patients were based on the patients' final diagnoses (recovered, length of hospital stay (LOHS), progression of severity and mortality).
167 non-critically ill COVID-19 patients were included in the analysis, of which 52.7% are admitted under the COVID-19 severe group and 47.3% for COVID-19 Mild/Moderate. Mostly are male (53.3%) with an average body mass index (BMI) of 24.26 (SD = 3.52) and have hypertension (55.1%) and diabetes (42.5%). Among the nutritional biomarker, albumin (p = 0.028; p = 0.004), total lymphocyte count (TLC) (p = 0.013; p = 0.005) and BUN (p = 0.001; p=<0.001) were shown to be significantly associated with progression of severity and mortality. Univariate logistic regression analysis showed the following nutritional prognostic score were correlated. (1.) progression of COVID-19 severity: PNI score (OR 0.928, 95% CI 0.886, 0.971, p=<0.001), and BAR value (OR 1.130, 95% CI 1.027, 1.242, p = 0.012); (2.) Mortality: PNI score (OR 0.926, 95% CI 0.878, 0.977, p = 0.005), CAR (OR 1.809, 95% CI 1.243, 2.632, p = 0.002), and BAR (OR 1.180, 95% CI 1.077, 1.292, p=<0.001). The average LOHS of COVID-19 patients was 12 days (SD = 7.72). However, it does not show any significant correlation between any nutritional biomarker, prognostic indices and LOHS.
This study demonstrated that deranged level of nutritional biomarkers can affect patient's COVID-19 severity and associated with patient's clinical outcome. Low albumin (≤2.5 g/dL), low level of TLC (≤1500 cells/mm3), elevated BUN (≥7.1 mmol/L) are associated with patient's case severity progression and mortality while low PNI score (<42.49), high BAR value (≥2.8) and CAR value (≥2.04) provided an important nutritional prognostic information and could predict mortality which can be a useful parameter in admission, hence it is recommended to screen all COVID-19 patients to reduce mortality.
世界卫生组织(WHO)定义的营养不良包括营养不足。在菲律宾,由于多种因素,营养不良很常见。营养生物标志物可用作膳食摄入和营养状况的替代指标,可以检测到 COVID-19 患者支持临床管理的不足。除此之外,生物标志物对于 COVID-19 患者的筛查、临床管理和严重并发症的预防具有潜在的用途。血清白蛋白、C 反应蛋白(CRP)、白细胞计数、淋巴细胞计数、血尿素氮(BUN)用于计算营养预后指数(预后营养指数(PNI)评分、BUN/Albumin 比值(BAR)和 CRP/Albumin 比值(CAR)。
比较 COVID-19 患者的营养生物标志物,根据病例严重程度进行评估,并确定营养预后指数并与患者住院期间的临床结局相关联。
这是一项 2021 年 6 月至 2021 年 8 月在卡拉巴松地区的 COVID-19 指定转诊中心进行的单中心、横断面研究,该研究共纳入 167 例患者,作为研究的一部分,对患者入院前 48 小时的临床指标进行了评估,包括患者的年龄、性别、合并症、体重、身高、实验室和血清生物标志物(血清白蛋白、白细胞计数、淋巴细胞计数、CRP 和 BUN),并计算和分析了营养预后指数。患者的临床结局基于患者的最终诊断(康复、住院时间(LOHS)、严重程度进展和死亡率)。
纳入了 167 例非危重症 COVID-19 患者进行分析,其中 52.7%为 COVID-19 重症组,47.3%为 COVID-19 轻症/中度组。大多数患者为男性(53.3%),平均 BMI 为 24.26(SD=3.52),合并高血压(55.1%)和糖尿病(42.5%)。在营养生物标志物中,白蛋白(p=0.028;p=0.004)、总淋巴细胞计数(TLC)(p=0.013;p=0.005)和 BUN(p=0.001;p<0.001)与严重程度进展和死亡率显著相关。单变量逻辑回归分析显示,以下营养预后评分与 COVID-19 严重程度进展相关:(1)PNI 评分(OR 0.928,95%CI 0.886,0.971,p<0.001)和 BAR 值(OR 1.130,95%CI 1.027,1.242,p=0.012);(2)死亡率:PNI 评分(OR 0.926,95%CI 0.878,0.977,p=0.005)、CAR(OR 1.809,95%CI 1.243,2.632,p=0.002)和 BAR(OR 1.180,95%CI 1.077,1.292,p<0.001)。COVID-19 患者的平均 LOHS 为 12 天(SD=7.72)。然而,任何营养生物标志物、预后指数与 LOHS 之间均无显著相关性。
本研究表明,营养生物标志物的改变可能会影响 COVID-19 患者的严重程度,并与患者的临床结局相关。低白蛋白(≤2.5 g/dL)、低 TLC 水平(≤1500 细胞/mm3)、高 BUN(≥7.1 mmol/L)与患者病情进展和死亡率相关,而低 PNI 评分(<42.49)、高 BAR 值(≥2.8)和 CAR 值(≥2.04)则提供了重要的营养预后信息,并可预测死亡率,这可能是入院时有用的参数,因此建议筛查所有 COVID-19 患者,以降低死亡率。